|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 701 PENNSYLVANIA AVENUE, NW |
Address2 | SUITE 720 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 9237-12
|
||||||||
|
6. House ID# 316700000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Kristin Julason Damato |
Date | 7/22/2019 5:14:12 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations.
-Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
-Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
-Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P).
-Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act.
-Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act.
-Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristin |
Julason Damato |
|
|
|
Brendan |
Devine |
|
|
|
Karen Lynn |
Nonnemaker |
|
|
|
Jill |
Canino Kaleta |
|
|
|
David |
Schwartz |
|
|
|
Kathryn |
Gallagher |
|
|
|
Courtney |
Lawrence |
|
|
|
Sergio |
Santiviago |
|
|
|
Gary |
Kline |
|
|
|
Emily |
Katz |
|
|
|
Chris |
Davis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
-Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions.
-21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability.
-Implementation of the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), as amended by the Affordable Care Act, the 21st Century Cures Act, and ERISA, including DOL proposed FAQs about Mental Health and Substance Use Disorder Parity Implementation.
-Issues related to H.R. 861, the End Surprise Billing Act and "No Surprises Act" Discussion Draft.
-Issues related to 42 C.F.R. Part 2, in H.R. 2062, The Overdose Prevention and Patient Safety Act and S. 1012, the the Protecting Jessica Grubbs Legacy Act.
-Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristin |
Julason Damato |
|
|
|
Brendan |
Devine |
|
|
|
Jill |
Canino Kaleta |
|
|
|
David |
Schwartz |
|
|
|
Kathryn |
Gallagher |
|
|
|
Courtney |
Lawrence |
|
|
|
Sergio |
Santiviago |
|
|
|
Emily |
Katz |
|
|
|
Chris |
Davis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
-Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act.
-H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans.
-S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristin |
Julason Damato |
|
|
|
Brendan |
Devine |
|
|
|
Kathryn |
Gallagher |
|
|
|
Courtney |
Lawrence |
|
|
|
Sergio |
Santiviago |
|
|
|
Emily |
Katz |
|
|
|
Chris |
Davis |
|
|
|
Jill |
Canino Kaleta |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA).
-Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.
-Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models.
-Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019.
-Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act.
-H.R. 2279, Safe Step Act (Step Therapy Bill).
-Pharmacy issues related to S. 1895, the Lower Health Care Costs Act.
-Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.
17. House(s) of Congress and Federal agencies Check if None
Centers For Medicare and Medicaid Services (CMS), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristin |
Julason Damato |
|
|
|
Brendan |
Devine |
|
|
|
Karen Lynn |
Nonnemaker |
|
|
|
David |
Schwartz |
|
|
|
Kathryn |
Gallagher |
|
|
|
Courtney |
Lawrence |
|
|
|
Sergio |
Santiviago |
|
|
|
Gary |
Kline |
|
|
|
Emily |
Katz |
|
|
|
Chris |
Davis |
|
|
|
Lisa |
Le Gette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Developments regarding Korean Trade Agreement (KORUS), China trade and tariffs, NAFTA.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Merski |
|
|
|
Kristin |
Julason Damato |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Pharmacy issues related to S. 1215 and H.R. 2500, the National Defense Authorization Act for Fiscal Year 2020.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Emily |
Katz |
|
|
|
Chris |
Davis |
|
|
|
Lisa |
Le Gette |
|
|
|
Brendan |
Devine |
|
|
|
Kathryn |
Gallagher |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
Issues related to paid family leave and H.R. 1185/S. 463, the FAMILY Act and competition in health care.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brendan |
Devine |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
Express Scripts, Inc. |
|
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |